Business Context and Reporting Period
Company: Tivic Health Systems, Inc. (Note: Input metadata referenced "Valion Bio," but the filing text identifies the registrant as Tivic Health Systems, Inc., trading as TIVC).
Reporting Period: Quarterly Report on Form 10-Q for the period ended June 30, 2025.
Business Overview: Tivic is a diversified immunotherapeutics company. Its portfolio includes the FDA-approved over-the-counter device "ClearUP" for sinus pain relief and a bioelectronic program for non-invasive vagus nerve stimulation. In early 2025, the company pivoted significantly by acquiring an exclusive worldwide license for Entolimod, a late-stage TLR5 agonist for Acute Radiation Syndrome (ARS), and exercising an option for the neutropenia indication.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $156 | $474 |
| Cost of Sales | $52 | $277 |
| Gross Profit | $104 | $197 |
| Gross Margin | 66.7% | 41.6% |
| Net Loss | $(3,433) | $(2,747) |
| Net Loss Per Share (Basic & Diluted) | $(4.64) | $(17.05) |
| Cash and Cash Equivalents (End of Period) | $1,184 | $3,693 |
| Working Capital | $1,021 | $2,367 |
| Total Assets | $4,508 | $2,807 |
| Accumulated Deficit | $(46,975) | $(40,633) |
Debt and Liquidity: The company has no long-term debt listed on the balance sheet. Total liabilities are $821,000, consisting entirely of current liabilities (Accounts Payable and Accrued Expenses). The company reported a net cash outflow from operating activities of $2.7 million for the six months ended June 30, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 67% ($318,000) compared to the prior year period. This was driven by a 69% decrease in unit sales of the ClearUP device, as the company intentionally reduced advertising spend to reallocate capital toward its biopharmaceutical program.
- Expense Increase: Total operating expenses increased by 20% ($600,000) year-over-year. Research and Development (R&D) expenses surged by 77% ($432,000) due to the acquisition of the Entolimod license and associated development costs. General and Administrative (G&A) expenses increased by 16% ($275,000) due to higher professional fees and corporate expenses related to Nasdaq compliance and shareholder meetings.
- Asset Acquisition: Total assets increased by $1.7 million, primarily due to the capitalization of $2.2 million in "Licensed Technology" (Entolimod) acquired from Statera Biopharma.
- Stock Structure: The company implemented a 1-for-17 reverse stock split effective March 7, 2025. All share and per-share data in the filing have been retroactively restated.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. With cash of $1.2 million and a burn rate resulting in a $3.4 million net loss for the half-year, the company expects to require additional capital to fund operations and development.
- Strategic Pivot: The company plans to reduce spending on the ClearUP consumer business and may seek a strategic divestiture or exit of this segment by the end of 2025. The primary focus is now on advancing Entolimod (ARS and neutropenia) and the non-invasive vagus nerve stimulation platform.
- Financing Activities: The company has secured a $25 million Equity Line of Credit with Mast Hill Fund and a tranched financing agreement for up to $8.4 million via Series B Preferred Stock. As of June 30, 2025, the first tranche of the preferred stock financing ($700,000) had closed. Subsequent events noted a second tranche closing in July 2025.
- Commitments: The company has significant future payment obligations, including milestone payments to Statera (up to $8.25 million total potential) and a manufacturing agreement with Scorpius BioManufacturing estimated at $4.1 million total investment.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting as of December 31, 2024, attributed to the small size of the accounting team.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash ($1.2M) against the disclosed burn rate and upcoming milestone payments to Statera and Scorpius.
- Financing Execution: Confirm the status of the remaining tranches of the $8.4 million Preferred Stock financing and the utilization of the $25 million Equity Line of Credit.
- ClearUP Divestiture: Monitor for announcements regarding the strategic exit or monetization of the ClearUP consumer business, which is currently the sole revenue source.
- Entolimod Progress: Track the timeline for the validation of manufacturing processes and the filing of the Biologics License Application (BLA) for Acute Radiation Syndrome.
- Internal Controls: Review subsequent filings for remediation of the material weakness in internal controls over financial reporting.